New LLS Docuseries on CAR T-cell Advances Aims to Educate and Empower Blood Cancer Patients

First-hand Patient Accounts Provide Unique Insight

WASHINGTON, March 4, 2025 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) has launched a new docuseries to inform blood cancer patients, caregivers, healthcare providers, and the public about the revolutionary progress of CAR T-cell therapy.

Through an array of emotional patient stories and an interview with immunologist and oncologist Carl June, M.D., of Penn Medicine, this 3-part mini-series aims to educate the public about the treatment advances in blood cancer, in particular CAR-T and other cell therapies. Dr. June helped pioneer CAR T-cell therapy with LLS research funding support.

Immunotherapy, like CAR T-cell therapy, harnesses the power of the patient's own immune system to treat blood cancer. It has evolved into a standard treatment option that can benefit some blood cancer patients. CAR T offers patients tremendous hope and even the potential for a cure for some whose cancer would have otherwise been fatal.

"The Leukemia & Lymphoma Society was one of the first to invest in CAR T-cell therapy research back in the 1990s because our scientists recognized its potential to be a life-changing treatment," says Lore Gruenbaum, Ph.D., LLS's chief scientific officer. "Since its first FDA approval in 2017, CAR-T has become available to treat a variety of blood cancers and has given new hope to patients who had run out of treatment options."

This free docuseries, CAR T-cell Therapy: a Path of Hope and Healing, will be available on LLS.org. The series will live among a catalogue of other educational videos that LLS has produced to inform people about the latest blood cancer updates, treatments, survivorship, and much more.

The docuseries, which was created in collaboration with PIXACORE, a marketing and medical communications healthcare agency, would not have been possible without the critical support of our partners: Kite, a Gilead Company, Bristol Myers Squibb, Johnson & Johnson, and Legend Biotech.

Educating Patients is an Important Step Toward a Bold Goal

Recently, LLS announced its bold goal for the future: to enable blood cancer patients to gain more than one million years of life by 2040.

Gaining one million years of life means more birthdays, graduations, weddings, holidays and memories shared with family and friends.

Educating patients about the latest treatment options is pivotal for equipping people with the knowledge needed to make informed decisions, in consultation with their care team, about which treatments are best for them.

LLS has more than 75 years of history in educating patients and their families through programs like this, including our Information Resource Center. Our dedication to robust research funding and patient financial support positions us well to achieve this bold goal.

To achieve this bold goal, however, we must unite as a community to accelerate cures and treatments, improve healthcare delivery and educate and support all patients.

"An educated patient is often an empowered patient," says Elisa Weiss, Ph.D., senior vice president of Education, Services & Health Research at LLS. "An empowered patient is more likely to advocate for themselves, ask questions and approach their healthcare team when they believe something is wrong. We can help accelerate LLS's bold goal by providing free educational materials, like this docuseries, to guide as many patients as possible through their diagnosis and beyond."

Visit CARTHopeAndHealing.com to watch the 15-minute docuseries and view LLS's other educational videos here.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society^® (LLS) is the global leader in the fight against blood cancer. The LLS mission: Cure blood cancer and improve the quality of life of all patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949, LLS has regions throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

For additional information, visit lls.org/lls-newsnetwork. Follow us on Facebook, X, Instagram, LinkedIn and TikTok.

About PIXACORE

PIXACORE is an independent, full-service healthcare marketing and medical communications agency dedicated to advancing breakthroughs in healthcare. With deep expertise in oncology and cell and gene therapies, including CAR T-cell therapy, PIXACORE partners with biotech, pharmaceutical, and health organizations to deliver strategic, impactful solutions that educate, engage, and inspire. Their services span brand marketing, medical communications, omnichannel strategy, scientific exchange, and innovative storytelling. PIXACORE's mission is to enhance lives by transforming complex science into meaningful communications that resonate with healthcare professionals, patients, and caregivers. For more information, visit pixacore.com.

LLS Media Contact:
Ryan McDonald
[email protected]

PIXACORE Media Contact:
Marty Murphy
[email protected]

SOURCE The Leukemia & Lymphoma Society (LLS)